Compare BLCO & STWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | STWD |
|---|---|---|
| Founded | 1853 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.4B |
| IPO Year | 2022 | 2009 |
| Metric | BLCO | STWD |
|---|---|---|
| Price | $16.32 | $18.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $18.45 | ★ $20.00 |
| AVG Volume (30 Days) | 358.5K | ★ 2.4M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 10.64% |
| EPS Growth | N/A | ★ 4.55 |
| EPS | N/A | ★ 1.15 |
| Revenue | ★ $5,101,000,000.00 | $1,844,289,000.00 |
| Revenue This Year | $8.65 | $283.44 |
| Revenue Next Year | $5.59 | $17.66 |
| P/E Ratio | ★ N/A | $15.98 |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $10.83 | $16.90 |
| 52 Week High | $18.92 | $20.99 |
| Indicator | BLCO | STWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 59.14 |
| Support Level | $16.26 | $18.28 |
| Resistance Level | $17.11 | $18.62 |
| Average True Range (ATR) | 0.47 | 0.24 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 56.18 | 74.80 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.